Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
PIK3CA and breast cancer are reported together in 20 articles.
Gene
PIK3CA
- HGNC
- HGNC:8975
77articles
77mentions
4variants with confirmed gene link
Most co-reported phenotypes (articles)
breast cancer 20colorectal cancer 16thyroid cancer 8lung cancer 4diabetes mellitus 3hepatocellular carcinoma 2ovarian cancer 2asthma 1
Reported variants (articles · ClinVar status)
Phenotype
Breast cancer
1,211articles
1,211mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
20 records shown · first 60Post-CDK4/6 Inhibitor Therapeutic Approaches in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Current Evidence and Emerging Strategies-A Narrative Review.
PMID 42351448 | PMCID PMC13298351 | DOI 10.3390/diagnostics16121790 · Diagnostics (Basel, Switzerland) · 2026 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “Elacestrant improved progression-free survival in ESR1-mutated disease in the EMERALD trial, capivasertib plus fulvestrant demonstrated significant benefit in tumors harboring AKT/PIK3CA/PTEN pathway alterations in CAPItello-291, and inavolisib plus palbociclib and fulvestrant achieved both progression-free and overall survival improvement in PIK3CA-mutated patients with early relapse in INAVO120.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Post-CDK4/6 Inhibitor Therapeutic Approaches in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Current Evidence and Emerging Strategies-A Narrative Review.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CDK4 | “Background: Therapeutic resistance following cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) represents a key unmet need in hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC).” | 0.98 | hgnc_dict_v1 |
| gene | PTEN | “Elacestrant improved progression-free survival in ESR1-mutated disease in the EMERALD trial, capivasertib plus fulvestrant demonstrated significant benefit in tumors harboring AKT/PIK3CA/PTEN pathway alterations in CAPItello-291, and inavolisib plus palbociclib and fulvestrant achieved both progression-free and overall survival improvement in PIK3CA-mutated patients with early relapse in INAVO120.” | 0.98 | hgnc_dict_v1 |
Clinicopathological Landscape and Survival Outcomes of HER2-Low Breast Cancer in a Large Arab Cohort.
PMID 41792988 | DOI 10.1002/wjs.70267 · World journal of surgery · 2026 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “Clinicopathological characteristics, biomarker profiles (ER, PR, Ki-67), molecular alterations (PIK3CA, TP53, BRCA) and survival outcomes (overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), and distant disease-free survival (DDFS)) were compared.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Clinicopathological Landscape and Survival Outcomes of HER2-Low Breast Cancer in a Large Arab Cohort.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | TP53 | “Clinicopathological characteristics, biomarker profiles (ER, PR, Ki-67), molecular alterations (PIK3CA, TP53, BRCA) and survival outcomes (overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), and distant disease-free survival (DDFS)) were compared.” | 0.98 | hgnc_dict_v1 |
| population | Saudi Arabia | “METHODS: We retrospectively analyzed 1097 Saudi breast cancer patients for HER2 status by immunohistochemistry (IHC), classifying tumors as HER2-zero (IHC 0) or HER2-low (IHC 1+/2+ and FISH-negative). CONCLUSION: In this large, ethnically homogenous Saudi cohort, HER2-low breast cancer represents a distinct molecular and clinicopathological subtype with luminal like features, yet no prognostic advantage.” | 0.95 | saudi_context_rules_v1 |
Multitargeted comparative evaluation suggests 2-Aoeobenoxmide shows favourable in silico binding compared to Tucatinib against ERα, HER2, AKT1, EGFR, and PIK3CA in breast cancer.
PMID 42310133 | PMCID PMC13547228 | DOI 10.1038/s41598-026-57604-0 · Scientific reports · 2026 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “Multitargeted comparative evaluation suggests 2-Aoeobenoxmide shows favourable in silico binding compared to Tucatinib against ERα, HER2, AKT1, EGFR, and PIK3CA in breast cancer.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Multitargeted comparative evaluation suggests 2-Aoeobenoxmide shows favourable in silico binding compared to Tucatinib against ERα, HER2, AKT1, EGFR, and PIK3CA in breast cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | AKT1 | “Multitargeted comparative evaluation suggests 2-Aoeobenoxmide shows favourable in silico binding compared to Tucatinib against ERα, HER2, AKT1, EGFR, and PIK3CA in breast cancer.” | 0.98 | hgnc_dict_v1 |
| gene | EGFR | “Multitargeted comparative evaluation suggests 2-Aoeobenoxmide shows favourable in silico binding compared to Tucatinib against ERα, HER2, AKT1, EGFR, and PIK3CA in breast cancer.” | 0.98 | hgnc_dict_v1 |
Genomic Landscape of Advanced Solid Tumors in Middle East and North Africa Using Circulating Tumor DNA in Routine Clinical Practice.
PMID 39342926 | PMCID PMC12140595 | DOI 10.1159/000541571 · Oncology · 2025 · 14 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “EGFR (10.2%), FGFR1 (4.9%), and PIK3CA (4.9%) showed the most amplifications, while fusions were observed in 2.7% of patients, including ALK, FGFR2, and RET.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “In patients with breast cancer, PIK3CA (35.3%), ESR1 (21.7%), and BRCA1/2 (13.3%) had the most prevalent alterations among NCCN-recommended genes.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | TP53 | “RESULTS: In the pan-cancer group, TP53 (58.5%), EGFR (20.4%), and KRAS (18.9%) were the most frequently mutated genes.” | 0.98 | hgnc_dict_v1 |
| gene | EGFR | “RESULTS: In the pan-cancer group, TP53 (58.5%), EGFR (20.4%), and KRAS (18.9%) were the most frequently mutated genes.” | 0.98 | hgnc_dict_v1 |
Tailored therapies for triple-negative breast cancer: current landscape and future perceptions.
PMID 40029385 | DOI 10.1007/s00210-025-03896-4 · Naunyn-Schmiedeberg's archives of pharmacology · 2025 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “The molecular landscape of TNBC is covered in the first section, which keeps the focus on transcriptome and genomic profiling while highlighting key molecular targets like mutations in the BRCA1/2, PIK3CA, androgen receptors (AR), epidermal growth factor receptors (EGFR), and immunological checkpoint molecules.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Tailored therapies for triple-negative breast cancer: current landscape and future perceptions.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | BRCA1 | “The molecular landscape of TNBC is covered in the first section, which keeps the focus on transcriptome and genomic profiling while highlighting key molecular targets like mutations in the BRCA1/2, PIK3CA, androgen receptors (AR), epidermal growth factor receptors (EGFR), and immunological checkpoint molecules.” | 0.98 | hgnc_dict_v1 |
| gene | AR | “The molecular landscape of TNBC is covered in the first section, which keeps the focus on transcriptome and genomic profiling while highlighting key molecular targets like mutations in the BRCA1/2, PIK3CA, androgen receptors (AR), epidermal growth factor receptors (EGFR), and immunological checkpoint molecules.” | 0.98 | hgnc_dict_v1 |
Thymol and Carvacrol: Molecular Mechanisms, Therapeutic Potential, and Synergy With Conventional Therapies in Cancer Management.
PMID 40964147 | PMCID PMC12436185 | DOI 10.1002/fsn3.70936 · Food science & nutrition · 2025 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “Thymol derivatives, such as 1,2,3-triazoles and carvacrol, effectively target breast cancer (BC) through PI3K/AKT/mTOR and NOTCH pathways and inhibit PIK3CA expression.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Thymol derivatives, such as 1,2,3-triazoles and carvacrol, effectively target breast cancer (BC) through PI3K/AKT/mTOR and NOTCH pathways and inhibit PIK3CA expression.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | XIAP | “They upregulate pro-apoptotic genes (Bax, Bak, Bid, p53, and SIVA) while downregulating anti-apoptotic genes (Bcl-2, Bcl-xL, XIAP, and cIAP1), leading to apoptosis and cell cycle arrest at G0/G1 and G2/M phases.” | 0.98 | hgnc_dict_v1 |
| phenotype | lung cancer | “In lung cancer (LC), they act as SphK1 inhibitors in NSCLC H1299 and A549 cell lines.” | 0.98 | phenotype_alias_lexicon_v2 |
Area deprivation index and breast cancer outcomes among patients in Western New York.
PMID 40544410 | PMCID PMC12259720 | DOI 10.1007/s10549-025-07733-3 · Breast cancer research and treatment · 2025 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “Finally, prevalence of somatic mutations in TP53, PIK3CA, and ESR1 were higher in ADI ≥ 60.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Area deprivation index and breast cancer outcomes among patients in Western New York.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | TP53 | “Finally, prevalence of somatic mutations in TP53, PIK3CA, and ESR1 were higher in ADI ≥ 60.” | 0.98 | hgnc_dict_v1 |
| gene | ESR1 | “Finally, prevalence of somatic mutations in TP53, PIK3CA, and ESR1 were higher in ADI ≥ 60.” | 0.98 | hgnc_dict_v1 |
Structure-Based In Silico Approaches Reveal IRESSA as a Multitargeted Breast Cancer Regulatory, Signalling, and Receptor Protein Inhibitor.
PMID 38399423 | PMCID PMC10891917 | DOI 10.3390/ph17020208 · Pharmaceuticals (Basel, Switzerland) · 2024 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “In our research, we conducted a comprehensive screening using HTVS, SP, and XP, followed by an MM/GBSA computation of human-approved drugs targeting HER2/neu, BRCA1, PIK3CA, and ESR1.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Structure-Based In Silico Approaches Reveal IRESSA as a Multitargeted Breast Cancer Regulatory, Signalling, and Receptor Protein Inhibitor.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | BRCA1 | “In our research, we conducted a comprehensive screening using HTVS, SP, and XP, followed by an MM/GBSA computation of human-approved drugs targeting HER2/neu, BRCA1, PIK3CA, and ESR1.” | 0.98 | hgnc_dict_v1 |
| gene | ESR1 | “In our research, we conducted a comprehensive screening using HTVS, SP, and XP, followed by an MM/GBSA computation of human-approved drugs targeting HER2/neu, BRCA1, PIK3CA, and ESR1.” | 0.98 | hgnc_dict_v1 |
Mutational Landscape and In-Silico Analysis of TP53, PIK3CA, and PTEN in Patients with Breast Cancer from Khyber Pakhtunkhwa.
PMID 38024667 | PMCID PMC10652387 | DOI 10.1021/acsomega.3c07472 · ACS omega · 2023 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “Mutational Landscape and In-Silico Analysis of TP53, PIK3CA, and PTEN in Patients with Breast Cancer from Khyber Pakhtunkhwa.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Mutational Landscape and In-Silico Analysis of TP53, PIK3CA, and PTEN in Patients with Breast Cancer from Khyber Pakhtunkhwa.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | TP53 | “Mutational Landscape and In-Silico Analysis of TP53, PIK3CA, and PTEN in Patients with Breast Cancer from Khyber Pakhtunkhwa.” | 0.98 | hgnc_dict_v1 |
| gene | PTEN | “Mutational Landscape and In-Silico Analysis of TP53, PIK3CA, and PTEN in Patients with Breast Cancer from Khyber Pakhtunkhwa.” | 0.98 | hgnc_dict_v1 |
Detection of genetic mutations in patients with breast cancer from Saudi Arabia using Ion AmpliSeq™ Cancer Hotspot Panel v.2.0.
PMID 35251613 | PMCID PMC8889543 | DOI 10.3892/br.2022.1509 · Biomedical reports · 2022 · 7 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “Mutations were predominantly focused on two genes, PIK3CA and TP53, in the BC genomes of the sample set.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Detection of genetic mutations in patients with breast cancer from Saudi Arabia using Ion AmpliSeq™ Cancer Hotspot Panel v.2.0.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | TP53 | “Mutations were predominantly focused on two genes, PIK3CA and TP53, in the BC genomes of the sample set.” | 0.98 | hgnc_dict_v1 |
| population | Saudi Arabia | “Detection of genetic mutations in patients with breast cancer from Saudi Arabia using Ion AmpliSeq™ Cancer Hotspot Panel v.2.0. Genomic DNA was extracted from the peripheral blood of 32 Saudi Arabian BC patients with histologically confirmed invasive BC stages I-III and IV, as well from 32 healthy Saudi Arabian women using a QIAamp® DNA Mini Kit.” | 0.95 | saudi_context_rules_v1 |
Implementation of Next-Generation Sequencing in Saudi Arabia for HER2-Positive Breast Cancer.
PMID 35280536 | PMCID PMC8913378 | DOI 10.1016/j.sjbs.2021.10.044 · Saudi journal of biological sciences · 2022 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “We used TruSight Tumor 15 using Next-Generation Sequencing (NGS) to look at genetic changes in 126 Saudi women with stage I to IV breast cancer. c-MET (p = 0.001), c-KIT (p = 0.001), and PIK3CA (p = 0.0001), were shown to be substantially linked with HER2 positive patients.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Implementation of Next-Generation Sequencing in Saudi Arabia for HER2-Positive Breast Cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | BRAF | “We also detected mutations in other genes, including BRAF, EGFR, and KRAS.” | 0.98 | hgnc_dict_v1 |
| gene | EGFR | “We also detected mutations in other genes, including BRAF, EGFR, and KRAS.” | 0.98 | hgnc_dict_v1 |
Investigation of the Anticancer Effect of α-Aminophosphonates and Arylidine Derivatives of 3-Acetyl-1-aminoquinolin-2(1H)-one on the DMBA Model of Breast Cancer in Albino Rats with In Silico Prediction of Their Thymidylate Synthase Inhibitory Effect.
PMID 35164019 | PMCID PMC8839308 | DOI 10.3390/molecules27030756 · Molecules (Basel, Switzerland) · 2022 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “Gene expression of GST-P, PCNA, PDK, and PIK3CA decreased in the DMBA group treated with α-aminophosphonates and arylidine derivatives of 3-acetyl-1-aminoquinolin-2(1H)-one, whereas PIK3R1 and BAX increased in the DMBA group treated with α-aminophosphonates and arylidine derivatives of 3-acetyl-1-aminoquinolin-2(1H)-one.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Investigation of the Anticancer Effect of α-Aminophosphonates and Arylidine Derivatives of 3-Acetyl-1-aminoquinolin-2(1H)-one on the DMBA Model of Breast Cancer in Albino Rats with In Silico Prediction of Their Thymidylate Synthase Inhibitory Effect.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | PCNA | “Gene expression of GST-P, PCNA, PDK, and PIK3CA decreased in the DMBA group treated with α-aminophosphonates and arylidine derivatives of 3-acetyl-1-aminoquinolin-2(1H)-one, whereas PIK3R1 and BAX increased in the DMBA group treated with α-aminophosphonates and arylidine derivatives of 3-acetyl-1-aminoquinolin-2(1H)-one.” | 0.98 | hgnc_dict_v1 |
| gene | PIK3R1 | “Gene expression of GST-P, PCNA, PDK, and PIK3CA decreased in the DMBA group treated with α-aminophosphonates and arylidine derivatives of 3-acetyl-1-aminoquinolin-2(1H)-one, whereas PIK3R1 and BAX increased in the DMBA group treated with α-aminophosphonates and arylidine derivatives of 3-acetyl-1-aminoquinolin-2(1H)-one.” | 0.98 | hgnc_dict_v1 |
Mutational pattern of PIK3CA exon 20 in circulating DNA in breast cancer.
PMID 35531214 | PMCID PMC9073026 | DOI 10.1016/j.sjbs.2022.01.002 · Saudi journal of biological sciences · 2022 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “Mutational pattern of PIK3CA exon 20 in circulating DNA in breast cancer.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Mutational pattern of PIK3CA exon 20 in circulating DNA in breast cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | RAC1 | “PIK3CA mutations were found to disrupt several pathways including RAC1, PDGF, Wnt, and integrin signalling.” | 0.98 | hgnc_dict_v1 |
Prognostic significance of heat shock protein 90AA1 (HSP90α) in invasive breast cancer.
PMID 33766957 | DOI 10.1136/jclinpath-2020-207106 · Journal of clinical pathology · 2022 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “RESULTS: High expression of HSP90ΑA1 both at the mRNA and protein levels was significantly associated with characteristics of BC poor prognosis, including high grade, lymphovascular invasion, poor Nottingham Prognostic Index and positive expression of p53 and PIK3CA.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Prognostic significance of heat shock protein 90AA1 (HSP90α) in invasive breast cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
Landscape of somatic mutations in breast cancer: new opportunities for targeted therapies in Saudi Arabian patients.
PMID 33868589 | PMCID PMC8021026 | DOI 10.18632/oncotarget.27909 · Oncotarget · 2021 · 14 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “Among the genes analyzed, the highest mutation rates were found in PIK3CA (12.9%), BRCA2 (11.7%), BRCA1 (10.2%), TP53 (6.0%), MSH2 (3.8%), PMS2 (3.8%), BARD1 (3.8%), MLH1 (3.4%), CDH1 (3.0%), RAD50 (3.0%), MSH6 (3.0%), NF1 (2.6%), in addition to others.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Landscape of somatic mutations in breast cancer: new opportunities for targeted therapies in Saudi Arabian patients.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | BRCA2 | “Among the genes analyzed, the highest mutation rates were found in PIK3CA (12.9%), BRCA2 (11.7%), BRCA1 (10.2%), TP53 (6.0%), MSH2 (3.8%), PMS2 (3.8%), BARD1 (3.8%), MLH1 (3.4%), CDH1 (3.0%), RAD50 (3.0%), MSH6 (3.0%), NF1 (2.6%), in addition to others.” | 0.98 | hgnc_dict_v1 |
| gene | BRCA1 | “Among the genes analyzed, the highest mutation rates were found in PIK3CA (12.9%), BRCA2 (11.7%), BRCA1 (10.2%), TP53 (6.0%), MSH2 (3.8%), PMS2 (3.8%), BARD1 (3.8%), MLH1 (3.4%), CDH1 (3.0%), RAD50 (3.0%), MSH6 (3.0%), NF1 (2.6%), in addition to others.” | 0.98 | hgnc_dict_v1 |
Helical and kinase domain mutations of PIK3CA, and their association with hormone receptor expression in breast cancer.
PMID 31404155 | PMCID PMC6676675 | DOI 10.3892/ol.2019.10565 · Oncology letters · 2019 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “Helical and kinase domain mutations of PIK3CA, and their association with hormone receptor expression in breast cancer.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Helical and kinase domain mutations of PIK3CA, and their association with hormone receptor expression in breast cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| population | Saudi Arabia | “A total of 118 tumor samples from confirmed breast cancer patients were collected from the histopathology laboratory at King Fahd Hospital of the University (Al-Khobar, Saudi Arabia). Three mutations, namely E542K and E545K within exon 9, and H1047R within exon 20, were observed in 25 patients (21.2%).” | 0.95 | saudi_context_rules_v1 |
| variant | E542K | “Three mutations, namely E542K and E545K within exon 9, and H1047R within exon 20, were observed in 25 patients (21.2%).” | 0.82 | literature_variant_regex_v2 |
Structural prediction, whole exome sequencing and molecular dynamics simulation confirms p.G118D somatic mutation of PIK3CA as functionally important in breast cancer patients.
PMID 31174159 | DOI 10.1016/j.compbiolchem.2019.05.012 · Computational biology and chemistry · 2019 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “Structural prediction, whole exome sequencing and molecular dynamics simulation confirms p.G118D somatic mutation of PIK3CA as functionally important in breast cancer patients.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Structural prediction, whole exome sequencing and molecular dynamics simulation confirms p.G118D somatic mutation of PIK3CA as functionally important in breast cancer patients.” | 0.98 | phenotype_alias_lexicon_v2 |
| variant | p.G118D | “Structural prediction, whole exome sequencing and molecular dynamics simulation confirms p.G118D somatic mutation of PIK3CA as functionally important in breast cancer patients.” | 0.95 | hgvs_regex_v1 |
| variant | p.E545A | “Most recurrent mutations found were known hotspot PIK3CA mutations with known clinical significance like p.E545 K, p.E545A, p.E545 G and p.C420R.” | 0.95 | hgvs_regex_v1 |
Overcoming endocrine resistance in hormone receptor-positive breast cancer.
PMID 29910644 | PMCID PMC6001756 | DOI 10.3747/co.25.3752 · Current oncology (Toronto, Ont.) · 2018 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “In some cases, resistance develops as a result of genetic or epigenetic alterations in various components of the signalling pathways, such as overexpression of her2 and erα co-activators, aberrant expression of cell-cycle regulators, and PIK3CA mutations.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Overcoming endocrine resistance in hormone receptor-positive breast cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.
PMID 26105797 | DOI 10.1007/s10549-015-3480-6 · Breast cancer research and treatment · 2015 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | PI3 | “The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.” | 0.98 | hgnc_dict_v1 |
Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.
PMID 23982433 | PMCID PMC3926885 | DOI 10.4161/cbt.25945 · Cancer biology & therapy · 2013 · 9 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PIK3CA | “Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.” | 0.98 | phenotype_alias_lexicon_v2 |
| variant | p.His1047Arg | “The majority of the mutations, 17 out of 21 (81%), were in exon 20 (p.His1047Arg, p.His1047Lys, p.Thr1025Ala, p.Gly1049Arg, p.Asp1056Asn) while the remainder, 4 out of 21 (19%) were in exon 9 (p.Glu545Lys).” | 0.95 | hgvs_regex_v1 |
| variant | p.His1047Lys | “The majority of the mutations, 17 out of 21 (81%), were in exon 20 (p.His1047Arg, p.His1047Lys, p.Thr1025Ala, p.Gly1049Arg, p.Asp1056Asn) while the remainder, 4 out of 21 (19%) were in exon 9 (p.Glu545Lys).” | 0.95 | hgvs_regex_v1 |